Q-omics provides the consensus-scored C18orf12 profile across patient tissues and cancer cell-line models. C18orf12 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, C18orf12 is differentially expressed in 1, with the highest sampling consensus in BLCA. Additionally, C18orf12 RNA expression shows 10,089 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, BLCA, and LSCC as cancer lineages where C18orf12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C18orf12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C18orf12 survival associations across molecular data types. C18orf12 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C18orf12 RNA expression–survival associations across cancer types. High C18orf12 expression shows unfavorable associations in LIHC, THYM, PCPG and READ, but favorable associations in SKCM and STAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for C18orf12 RNA expression.
This table summarizes C18orf12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for C18orf12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C18orf12 shows higher tumor expression in BLCA. The BLCA box plot shows higher C18orf12 RNA expression in tumor versus normal tissue (log2 FC = +0.102, t-test p = .046).
This table shows molecular features associated with C18orf12 in patient tissues and cancer cell lines. In patient samples, C18orf12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
